1. Home
  2. KALV vs BBN Comparison

KALV vs BBN Comparison

Compare KALV & BBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KalVista Pharmaceuticals Inc.

KALV

KalVista Pharmaceuticals Inc.

HOLD

Current Price

$26.80

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo BlackRock Taxable Municipal Bond Trust of Beneficial Interest

BBN

BlackRock Taxable Municipal Bond Trust of Beneficial Interest

HOLD

Current Price

$15.69

Market Cap

964.6M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
KALV
BBN
Founded
N/A
1983
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance Companies
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
964.6M
IPO Year
2014
2010

Fundamental Metrics

Financial Performance
Metric
KALV
BBN
Price
$26.80
$15.69
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$32.60
N/A
AVG Volume (30 Days)
5.4M
193.8K
Earning Date
07-09-2026
01-01-0001
Dividend Yield
N/A
6.90%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$50,000,000.00
N/A
Revenue This Year
$185.42
N/A
Revenue Next Year
$59.23
N/A
P/E Ratio
N/A
N/A
Revenue Growth
495.66
N/A
52 Week Low
$9.83
$15.47
52 Week High
$26.85
$17.45

Technical Indicators

Market Signals
Indicator
KALV
BBN
Relative Strength Index (RSI) 74.68 38.64
Support Level $14.25 $15.58
Resistance Level $26.85 $16.71
Average True Range (ATR) 0.07 0.14
MACD -0.22 -0.04
Stochastic Oscillator 71.05 31.05

Price Performance

Historical Comparison
KALV
BBN

About KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

About BBN BlackRock Taxable Municipal Bond Trust of Beneficial Interest

BlackRock Taxable Municipal Bond Trust is a diversified, closed-end management investment company. Its investment objective is to seek high current income, with a secondary objective of capital appreciation. The Trust seeks to achieve its investment objectives by investing in a portfolio of taxable municipal securities, including Build America Bonds (BABs), issued by state and local governments to finance capital projects such as public schools, roads, transportation infrastructure, bridges, ports and public buildings.

Share on Social Networks: